Discussion

Mitochondrial diseases are a range of disorders resulting from mitochondrial respiratory chain dysfunction, affecting energy-dependent organs like the myocardium, which relies on oxidative metabolism for its functions. ^{Reference Yang, Chen and Duan6} They exhibit a highly variable phenotype-genotype correlation with different organs affected and with a wide range of severity. Cardiac involvement may include not only the hypertrophic expression but also dilated, restrictive, and arrhythmogenic forms of cardiomyopathy. ^{Reference Yang, Chen and Duan6,Reference Meyers, Basha and Koenig7}

Our patient’s unique clinical picture, which was associated with severe cardiac symptoms, was associated with biallelic variants in the VARS2 gene, a rare cause of mitochondrial diseases, that has been linked to several clinical phenotypes, including mitochondrial encephalopathy, encephalocardiomyopathy, and isolated cardiomyopathy. This nuclear gene encodes a mitochondrial aminoacyl-tRNA synthetase that catalyses the binding of valine to tRNA for mitochondrial translation. This constitutes the first described case harbouring both [c.1100C > T (p.(Thr367Ile)) and c.1258G > A (p.(Ala420Thr))] in compound heterozygosity, as well as the association with hypertrophic cardiomyopathy. It is still unclear why genetic defects in transfer Ribonucleic acids (tRNAs) involved in mitochondrial DNA replication and expression can result in such different phenotypes. The role of mitochondrial tRNAs (mt-tRNAs) genetic variants in heart muscle disease is still poorly understood but may affect the 5' or 3' processing of tRNAs and induce structural and chemical modifications affecting respiratory chain complexes and consequently mitochondria, which in turn affects cardiomyocytes. ^{Reference Ding, Gao and Huang8}

The literature reports 24 cases of variants in VARS2 gene, including 18 pathogenic variants, with the most commonly described variant being the homozygous c.1100C > T (p. Thr367lle). ^{Reference Bruni, Di Meo and Bellacchio5,Reference Pereira, Adrião and Sampaio9,Reference Kušíková, Feichtinger and Csillag10} Kušíková and colleagues in 2021 accounted for 19 families with more than 23 affected individuals, 13 of whom were diagnosed with hypertrophic cardiomyopathy. They found that hypertrophic cardiomyopathy was present in 14 out of 15 cases in compound heterozygotes including the variant c.1100C > T (p. Thr367Ile). It was also shown that all homozygous for c.1258G > A variant had hypertrophic cardiomyopathy, but not the compound heterozygotes for this variant. Our patient presented a combination of both variants most commonly associated with Hypertrophic Cardiomyopathy suggesting that they may contribute to the pathological expression of cardiac disease and the severity of the involvement.

Three aspects of this case stand out from previously reported VARS2 gene variants: (1) a severe cardiac presentation with pericardial effusion and tamponade which has not yet been described; (2) complete regression of left ventricular hypertrophy with medical treatment; and (3) survival with no apparent deterioration of neurological, respiratory, or cardiovascular status to date.

The management of mitochondrial diseases is based on the treatment of symptoms and prevention of crisis, as well as dietary supplements such as coenzyme Q10, α-lipoic acid, vitamin C and vitamin E, vitamin B2 (riboflavin), l-arginine and l-citrulline, and creatine. Strategies and dosing vary greatly between institutions, and evidence about the benefit of using vitamins and supplements, besides the specific case of coenzyme Q10 deficiency disorders, is scarce. ^{Reference Meyers, Basha and Koenig7,Reference Parikh, Saneto and Falk11,Reference Quinzii, Emmanuele and Hirano12} Coenzyme Q10 supplementation in heart failure patients has also been used on the premise of energy depletion, so medications that can prevent this may have a role in their treatment. Nonetheless, data of moderate quality support the impact of coenzyme Q10 on lowering all-cause mortality, cardiovascular mortality, and heart failure hospitalisations. ^{Reference Sharma, Fonarow, Butler, Ezekowitz and Felker13,Reference Al Saadi, Assaf and Farwati14} The literature also mentions the use of standard heart failure therapy with β-blockers and angiotensin-converting enzyme inhibitors to treat cardiomyopathy in mitochondrial diseases. ^{Reference Meyers, Basha and Koenig7}

Our patient was treated with riboflavin (50 mg/day), ubidecarenone (10 mg/kg/day), and tapered diuretic therapy and showed a favourable course with normalisation of left ventricular dimensions and function without recurrence of pericardial effusion (Figs. 2 and 3).

Figure 2.

a and b – left ventricular (LV) hypertrophy (parasternal short axis and parasternal long axis, respectively); c and d – normal LV dimensions (PSAX and PLAX, respectively).

Figure 3.

Graphic representation of left ventricular (LV) function (Shortening fraction) and LV free wall Z-score (Boston Z-scores) with the timing of medical therapy initiation.

Cardiomyopathy indicates poor prognosis in mitochondrial diseases, with a higher mortality rate compared to patients without cardiac involvement (72% versus 25%) demonstrating that this subgroup of patients needs to be closely monitored. ^{Reference Kušíková, Feichtinger and Csillag10,Reference Imai-Okazaki, Kishita and Kohda15}

Cardiomyopathies are a very dynamic field and the genetic diagnosis of these diseases has proven to be valuable as it sometimes enables the development of targeted therapies.